Holen Sie sich die Stockscreener-App
0.77
4.19%
0.031
Handel nachbörslich:
.77
Schlusskurs vom Vortag:
$0.739
Offen:
$0.751
24-Stunden-Volumen:
2.75M
Relative Volume:
0.65
Marktkapitalisierung:
$167.09M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-90.60M
KGV:
-1.2285
EPS:
-0.6268
Netto-Cashflow:
$-68.88M
1W Leistung:
+6.18%
1M Leistung:
-9.67%
6M Leistung:
-59.47%
1J Leistung:
+51.75%
1-Tages-Spanne:
$0.73
$0.77
1-Wochen-Bereich:
$0.68
$0.78
52-Wochen-Spanne:
$0.36
$2.35
Tenaya Therapeutics Inc Stock (TNYA) Company Profile
Firmenname
Tenaya Therapeutics Inc
Sektor
Branche
Telefon
415-865-2066
Adresse
171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO
Compare TNYA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNYA
Tenaya Therapeutics Inc
|
0.77 | 160.36M | 0 | -90.60M | -68.88M | -0.6268 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-10 | Eingeleitet | William Blair | Outperform |
| 2023-11-30 | Eingeleitet | Leerink Partners | Outperform |
| 2022-06-15 | Eingeleitet | H.C. Wainwright | Buy |
Tenaya Therapeutics Inc Aktie (TNYA) Neueste Nachrichten
TNYA pulls back after hours following significant $1.13B deal-spurred rally - MSN
Tenaya Therapeutics (TNYA) Stock Analysis Report | Financials & Insights - Benzinga España
TNYA Stock Price, Quote & Chart | TENAYA THERAPEUTICS INC (NASDAQ:TNYA) - ChartMill
William Blair analysts confident on Tenaya Therapeutics (TNYA) product pipeline - MSN
Revenue Check: Is Tenaya Therapeutics Inc in a long term uptrendTreasury Yields & Community Consensus Stock Picks - baoquankhu1.vn
Investor Mood: Is Tenaya Therapeutics Inc stock a value trap2026 Levels & Real-Time Stock Price Movement Reports - baoquankhu1.vn
TNYA Technical Analysis | Trend, Signals & Chart Patterns | TENAYA THERAPEUTICS INC (NASDAQ:TNYA) - ChartMill
Pullback Watch: Is Tenaya Therapeutics Inc part of any ETF2026 Levels & Daily Profit Focused Stock Screening - baoquankhu1.vn
symbol__ Stock Quote Price and Forecast - CNN
Tenaya Therapeutics (TNYA) price target increased by 11.11% to 10.20 - MSN
William Blair Analysts Confident on Tenaya Therapeutics (TNYA) Product Pipeline - Yahoo Finance
Alnylam’s research pact worth up to $1.1B sends Tenaya higher - MSN
Tenaya Therapeutics, Inc. (TNYA) reports Q4 EPS of (12c), in line with consensus - MSN
Tenaya Therapeutics, Inc. (TNYA) Reports Q4 EPS of (12c), In Line with Consensus - Insider Monkey
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
How TN-301 Progress And Alnylam Deal At Tenaya Therapeutics (TNYA) Has Changed Its Investment Story - simplywall.st
Tenaya Therapeutics (NASDAQ:TNYA) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
What is Lifesci Capital's Estimate for TNYA Q1 Earnings? - MarketBeat
Outperform Maintained on Tenaya Therapeutics (TNYA) by Leerink and William Blair March 2026 - Meyka
TNYA Pulls Back After Hours Following Significant $1.13B Deal-Spurred Rally - Dailyhunt
Tenaya Therapeutics (TNYA) Valuation After TN-301 Data And New Alnylam Collaboration - simplywall.st
William Blair reiterates Outperform on Tenaya Therapeutics stock By Investing.com - Investing.com Australia
Leerink Partners reiterates Outperform on Tenaya stock at $2 - Investing.com UK
William Blair reiterates Outperform on Tenaya Therapeutics stock - Investing.com
Chardan Capital Reiterates Buy Rating for Tenaya Therapeutics (NASDAQ:TNYA) - MarketBeat
Tenaya Therapeutics Reports Promising 2025 Results, Advances Gene Therapy Programs, and Extends Cash Runway Into 2027 - Minichart
Tenaya Therapeutics (TNYA) Is Up 47.7% After Positive TN-301 DMD Data And Alnylam Deal - Yahoo Finance
Tenaya Therapeutics: Advancing Genetic Medicines and Small Molecule Therapies for Heart Disease Treatment - Minichart
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Bitget
Tenaya Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027 - TradingView
Tenaya Therapeutics (NASDAQ:TNYA) Issues Earnings Results, Meets Expectations - MarketBeat
Tenaya Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
TNYA: Clinical progress, Alnylam deal, and financing extend cash runway into 2027 - TradingView
Tenaya Therapeutics (NASDAQ: TNYA) narrows 2025 loss and extends cash runway to 2027 - Stock Titan
Finanzdaten der Tenaya Therapeutics Inc-Aktie (TNYA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):